The company recently acquired Adare Biome and its postbiotics portfolio.
Gut health will be one of the lead focuses for newly combined firm Dsm-Firmenich (Kaiseraugst, Switzerland) at the SupplySide West trade show happening October 23-27, 2023, in Las Vegas, booth #4764. One of the biggest highlights will be new postbiotic capabilities thanks to the company’s acquisition of Adare Biome this year.
Dsm-Firmenich says its gut health portfolio now spans postbiotics, human milk oligosaccharide (HMO) ingredients, prebiotics, and enzymes. “We’ve reimagined the approach to innovation in the gut health space, combining multi-ingredient solutions, leading-edge scientific expertise, and deep consumer insights designed to unlock the holistic health possibilities of the gut microbiome at every life stage,” said Penny Antonopoulos, senior director, marketing and business development, NA HNC, for the company.
She added, “Our acquisition of Adare Biome is a recent example of our investment to progress in this field. Now, we are able to harness the exciting possibilities of postbiotic products, propelling the dietary supplements sector toward delivering novel solutions.”
The first innovation to roll out is a “proprietary bacterial combination” called Humiome Post LB, which includes strains L. fermentum and L. delbrueckii, which Adare Biome developed using its patented ECHO process.
The company will also share its ingredient solutions for cognitive performance, omega-3 fatty acids, and women’s health at the show.
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.